Shopping Cart
- Remove All
- Your shopping cart is currently empty
SR 12460 is a lead NBD mimic, inhibiting the interaction between IKKβ and NEMO, suppressing TNF-α and LPS-induced NF-κB activation, and reducing LPS-induced acute pulmonary inflammation in mice.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $139 | 35 days | |
5 mg | $369 | In Stock | |
10 mg | $669 | 35 days | |
25 mg | $1,518 | 35 days |
Description | SR 12460 is a lead NBD mimic, inhibiting the interaction between IKKβ and NEMO, suppressing TNF-α and LPS-induced NF-κB activation, and reducing LPS-induced acute pulmonary inflammation in mice. |
In vitro | SR 12460 inhibited TNF-α-mediated NF-κB activation with a maximum median inhibitory concentration (IC50) of 11.34 μM. SR 12460 (50 μM) inhibits tumor necrosis factor α (TNF-α) and lipopolysaccharide (LPS) -induced NF-κB activation by blocking the interaction between IKKβ and NEMO. [1] |
In vivo | SR 12460 (10 mg/kg, intraperitoneal injection) inhibited LPS-induced acute lung inflammation in mice. SR 12460 (30 mg/kg intraperitoneally administered) significantly improved muscle function and muscle pathology in mdx mice. [1] |
Alias | SR12460 |
Molecular Weight | 325.74 |
Formula | C15H14ClF2N3O |
Cas No. | 2055101-66-9 |
Smiles | O=C(NC1=NC=C(Cl)C=C1)CNCCC=2C=C(F)C=C(F)C2 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMF: 8 mg/mL (24.56 mM), Sonication is recommended. DMSO: 8 mg/mL (24.56 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMF/DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.